Antiangiogenetic therapy for pediatric patients with inoperable benign tumors

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2008-006992-57-FI

Enrollment

Registered

2008-11-05

Start date

2009-01-16

Completion date

Unknown

Last updated

2024-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pediatric patients with inoperable benign tumors

Interventions

Trade Name: talidex Pharmaceutical Form: INN or Proposed INN: THALIDOMIDE CAS Number: 50351 Trade Name: celebra Pharmaceutical Form: INN or Proposed INN: CELECOXIB CAS Number: 169590425 Trade Name

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Finland

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026